Join Growin Stock Community!

Biocardia, inc.BCDA.US Overview

US StockHealthcare
(No presentation for BCDA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BCDA AI Insights

BCDA Overall Performance

BCDA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BCDA Recent Performance

-5.56%

Biocardia, inc.

-3.61%

Avg of Sector

-2.16%

S&P500

BCDA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BCDA Key Information

BCDA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BCDA Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.

Price of BCDA

BCDA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

BCDA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3089.53
PB Ratio
5.01
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-279700.00%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.47
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3089.53
PB Ratio
5.01
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-279700.00%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is BCDA's latest earnings report released?

    The most recent financial report for Biocardia, inc. (BCDA) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BCDA's short-term business performance and financial health. For the latest updates on BCDA's earnings releases, visit this page regularly.

  • How much debt does BCDA have?

    As of the end of the reporting period, Biocardia, inc. (BCDA) had total debt of 638K, with a debt ratio of 0.1. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BCDA have?

    At the end of the period, Biocardia, inc. (BCDA) held Total Cash and Cash Equivalents of 5.29M, accounting for 0.86 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BCDA's EPS continuing to grow?

    According to the past four quarterly reports, Biocardia, inc. (BCDA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.24. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BCDA?

    Biocardia, inc. (BCDA)'s Free Cash Flow (FCF) for the period is -1.67M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 36.01% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BCDA?

    The latest valuation data shows Biocardia, inc. (BCDA) has a Price-To-Earnings (PE) ratio of -1.62 and a Price/Earnings-To-Growth (PEG) ratio of 34.13. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.